TABLE 4.
Median overall survival (OS) and progression‐free survival (PFS) of the first‐line chemotherapy treatments
| Median OS, months (95% CI) | P‐value 1 | Hazard ratio (95% CI) | P‐value | Median PFS, months (95% CI) | P‐value 1 | Hazard ratio (95% CI) | P‐value | |
|---|---|---|---|---|---|---|---|---|
| First‐line chemo agents | .8 | .6 | ||||||
| Single | 11.0 (7.85‐13.17) | 1 | 3.4 (2.79‐4.73) | 1 | ||||
| Combination | 8.4 (5.49‐11.86) | 0.93 (0.59‐1.47) | .8 | 3.8 (1.91‐5.65) | 0.9 (0.59‐1.37) | .6 | ||
| First‐line chemo agents | .8 | .9 | ||||||
| Liposomal Doxorubicin | 10.6 (6.05‐17.58) | 1 | 2.8 (2.10‐5.39) | 1 | ||||
| Paclitaxel | 11.9 (7.85‐16.66) | 0.85 (0.53‐1.38) | .5 | 4.5 (3.19‐4.86) | 0.94 (0.60‐1.48) | .8 | ||
| Others | 7.4 (6.18‐11.86) | 0.88 (0.52‐1.49) | .6 | 3.0 (2.10‐4.53) | 1.02 (0.63‐1.66) | .9 | ||
| Unknown | 7.4 (NE) | 0.47 (0.06‐3.50) | .5 | NA | NA |
Abbreviations: NA, Not applicable; NE, Not estimable; NR, Not reached.
1
P‐value calculated using log‐rank test, excluding the category "Unknown."